bpc-157 fda is approved RFK Jr pushes for approval of peptide FDA commitee votes 8-6 to

The injectable form provides superior bioavailability compared to oral administration, making it the preferred choice for therapeutic applications

advanced schedules dose 250 mcg 2x daily

doses of other antidiabetic drugs may need adjustment

There are two distinct versions: CJC1295 with DAC Drug Affinity Complex extends the half-life to ~8 days, allowing weekly injections , but lacks pulsatility CJC1295 without DAC Shorter half-life (~30 minutes), ideal for physiological GH pulses , and preferred in performance enhancement settings For athletic performance and recovery, CJC1295 without DAC is most often chosen due to its compatibility with GHRP2 , MK677 , and BPC157